We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Front-Line Window of Opportunity Phase 2 Study of Sorafenib in Patients With Advanced Nonsmall Cell Lung Cancer.
- Authors
Dy, Grace K.; Hillman, Shauna L.; Rowland Jr., Kendrith M.; Molina, Julian R.; Steen, Preston D.; Wender, Donald B.; Nair, Suresh; Mandrekar, Sumithra; Schild, Steven E.; Adjei, Alex A.
- Abstract
This article discusses a study which assessed the efficacy and toxicity of sorafenib as front-line therapy in patients with stage IIIB or IV nonsmall cell lung cancer (NSCLC). The patients were given sorafenib continuously and were evaluated every two weeks during the first eight weeks. Only one partial response (PR) was observed in the first 20 patients. Of the 25 patients, there were three PR and six cases with stable disease observed. The study concluded that sorafenib is not effective as front-line therapy in the general unselected NSCLC population.
- Subjects
CANCER treatment; LUNG cancer; DRUG therapy; CANCER patients; RESEARCH
- Publication
Cancer (0008543X), 2010, Vol 116, Issue 24, p5686
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.25448